8-K: INmune Bio's INKmune Shows Promising Safety and NK-Cell Activation in Prostate Cancer Trial

INmune Bio reports positive initial safety and efficacy signals from the first cohort of its Phase I/II trial of INKmune in metastatic castration-resistant prostate cancer, showing increased NK cell activity.

Summary

• INmune Bio is conducting a Phase I/II trial (CaRe PC trial) for its NK cell therapy, INKmune, in men with metastatic Castration-Resistant Prostate Cancer (mCRPC).
• The first patient cohort in the trial has shown excellent safety, with all patients receiving treatment as outpatients without needing pre-medication.
• Blinded analysis of blood samples from the first three patients showed changes in the phenotype and function of their NK cells.
• Two out of three patients showed an increase in circulating activated NK cells, and all three showed increased NK cell function sustained for more than 40 days after the final INKmune infusion.
• One patient experienced a transient 21% decrease in PSA levels, which was associated with the increase in NK cell activity.
• The second dose-escalation cohort has completed dosing, and the third cohort is expected to begin in approximately 30 days.
• The dose of INKmune in the second and third cohorts is 3 and 5 times the dose of INKmune in the first cohort, respectively.
• All eight clinical sites are now open, and additional results from the higher dose cohorts will be released as they become available.

Sentiment

Score: 8

Explanation: The document presents positive initial results from a clinical trial, highlighting safety and efficacy signals. The tone is optimistic and forward-looking, suggesting a positive outlook for the company's technology.

Positives

• The trial demonstrated excellent safety with no need for pre-medication and outpatient treatment.
• INKmune showed clear evidence of persistent immunologic effects.
• There was an increase in circulating activated NK cells in two out of three patients.
• All three patients showed increased NK cell function sustained for more than 40 days.
• One patient had a 21% decrease in PSA levels, indicating a potential therapeutic effect.
• The trial is progressing as planned with the second cohort completed and the third cohort expected to start soon.

Risks

• The clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding is a risk to the company's operations and research.
• There is no guarantee that INKmune will be approved by the FDA or any regulatory body.

Future Outlook

The company plans to release additional results from the higher dose cohorts as they become available. The third cohort is expected to begin in approximately 30 days.

Management Comments

• Mark Lowdell, CSO and inventor of INKmune, said, 'The enrollment of the first cohort ran entirely in-line with our predicted timelines and confirmed the excellent safety profile with all patients receiving treatment as out-patient without the need for pre-medication of any kind.'
• Mark Lowdell also stated, 'Furthermore, even at this lowest dose of INKmune, there is clear evidence of persistent immunologic effects of INKmune treatment in these men with mCRPC.'

Industry Context

This announcement is significant in the context of the growing interest in NK cell therapies for cancer treatment. The positive safety and efficacy signals from the first cohort of the INKmune trial could position INmune Bio as a key player in this field.

Comparison to Industry Standards

• The reported safety profile of INKmune, with no pre-medication required and outpatient administration, is a positive differentiator compared to some other cell therapies that require more intensive patient management.
• The observed increase in NK cell activity and function, along with a PSA decrease in one patient, suggests a promising therapeutic effect, which is comparable to or better than some early-stage results seen in other NK cell therapy trials.
• Companies like Fate Therapeutics and Nkarta are also developing NK cell therapies, but INmune's approach of priming the patient's own NK cells is a unique strategy that could offer advantages in terms of safety and efficacy.

Stakeholder Impact

• Shareholders may view the positive initial results as a positive sign for the company's future prospects.
• Patients with mCRPC may see INKmune as a potential new treatment option.
• Employees may be encouraged by the progress of the clinical trial.

Next Steps

• The third dose-escalation cohort is expected to begin in approximately 30 days.
• Additional results from the higher dose cohorts will be released as they become available.

Key Dates

Keywords

INKmune, Natural Killer Cells, NK cells, Prostate Cancer, mCRPC, Immunotherapy, Clinical Trial, Phase I/II, Immunology, Cancer Treatment